OpGen Regains Compliance With Nasdaq Listing Requirements

GAITHERSBURG, Md., Feb. 05, 2018 -- OpGen, Inc. (NASDAQ:OPGN) announces that it has received notification from Nasdaq that the minimum bid price deficiency of the Company’s stock has been cured, and it will continue to be listed and traded on The Nasdaq Stock Market.  In addition, the Company has been informed that it is in compliance with all applicable listing standards of The Nasdaq Capital Market and that therefore its hearing before the Nasdaq Hearings Panel, which had been scheduled for February 8^th, has been cancelled.

About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment.

OpGen, and Acuitas are registered trademarks of OpGen, Inc. 

OpGen Contact:
Michael Farmer
Director, Marketing
240-813-1284
[email protected]
[email protected]

Investor Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]